JP Morgan Chase’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-629,541
| Closed | -$9.43M | – | 5069 |
|
|
2016
Q2 | $9.43M | Sell |
629,541
-15,485
| -2% | -$199K | ﹤0.01% | 1875 |
|
|
2016
Q1 | $7.85M | Sell |
645,026
-53,868
| -8% | -$755K | ﹤0.01% | 1919 |
|
|
2015
Q4 | $11.1M | Buy |
698,894
+10,365
| +2% | +$163K | ﹤0.01% | 1747 |
|
|
2015
Q3 | $10.6M | Sell |
688,529
-7,833
| -1% | -$169K | ﹤0.01% | 1716 |
|
|
2015
Q2 | $16.9M | Sell |
696,362
-25,963
| -4% | -$622K | ﹤0.01% | 1514 |
|
|
2015
Q1 | $16.8M | Sell |
722,325
-20,365
| -3% | -$539K | ﹤0.01% | 1552 |
|
|
2014
Q4 | $18.6M | Buy |
742,690
+74,252
| +11% | +$2.18M | ﹤0.01% | 1528 |
|
|
2014
Q3 | $20.8M | Sell |
668,438
-6,568
| -1% | -$178K | ﹤0.01% | 1421 |
|
|
2014
Q2 | $17.5M | Sell |
675,006
-44,023
| -6% | -$978K | ﹤0.01% | 1427 |
|
|
2014
Q1 | $16.8M | Buy |
719,029
+21,507
| +3% | +$470K | ﹤0.01% | 1431 |
|
|
2013
Q4 | $17.7M | Sell |
697,522
-318,621
| -31% | -$7.2M | 0.01% | 1406 |
|
|
2013
Q3 | $20.7M | Sell |
1,016,143
-22,510
| -2% | -$501K | 0.01% | 1307 |
|
|
2013
Q2 | $21.8M | Buy |
+1,038,653
| New | +$18.6M | 0.01% | 1202 |
|
JP Morgan Chase's SGNT Position: Q3 2016 in Review
JP Morgan Chase sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 629,541 shares — an estimated $9.43M sold.
JP Morgan Chase first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $21.8M in Q2 2013. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- JP Morgan Chase reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- JP Morgan Chase sold 629,541 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $9.43M.
- JP Morgan Chase first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- JP Morgan Chase's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $21.8M in Q2 2013.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on JP Morgan Chase's 13F filing for Q3 2016, filed 4 Nov 2016.